News By Tag
News By Place
Overall Pharmaceutical Contract Manufacturing Market will achieve revenues of $80.50 billion in 2019
The purpose of that report is to give forecasting that planners, influencers and leaders need. Visiongain is a business information publisher and consultancy in London, UK. It produces analysis to help companies and other organisations understand industries and their potentials.
In 2015, out of the contract manufacturing services assessed, active pharmaceutical ingredient (API) manufacturing continues to form the largest share of overall world revenue. And finished dose form (FDF) manufacturing shows the fastest growth. Developed countries gain the highest share of pharma production outsourcing. In 2015 North America holds the largest market share of the industry. The study shows that pharmaceutical companies will continue to outsource production to developed and developing countries. India and China expand CMO revenues at a faster rate than other countries, a trend likely to continue.
Shruti Tayal, a pharmaceutical industry analyst in visiongain, said: “The trend of mergers and acquisitions has increased and will continue from 2015, decreasing the number of CMOs. Pharmaceutical companies will continue to outsource some manufacturing operations to save time and money. Leading CMOs will capture most of the customers owing to integrated service offerings, also benefiting from consolidation in that pharma service industry. Active pharmaceutical ingredient production continues to form the largest revenue producing segment in pharma contract manufacturing, with final dosage form applications expanding at the fastest rate of revenue growth from 2015 to 2025, our study predicts.
“Leading CMOs also invest further into running operations in emerging regions such as India, China and Latin America. Those firms will increase competition in the developing national CMO markets. India and China are already prominent for contract production of APIs and FDFs for domestic use and export. That trend will continue, with opportunities also remaining for CMO operations in North America, Europe, Japan and other established markets, especially for high-value biological drug products.”
Visiongain’s new investigation identifies trends and revenue predictions at overall world market and individual company level. First the study gives discussions, financial analyses and commercial outlooks for 14 European CMOs, including these firms:
· Evonik Degussa
· Royal DSM
· Boehringer Ingelheim
· Vetter Pharma.
The report also shows developments and business outlooks for seven CMOs based in the US and Japan:
· Catalent Pharma Solutions
· Baxter BioPharma Solutions
· AbbVie Contract Manufacturing
· Pfizer CentreSource
· Daito Pharmaceutical
· Nipro Corporation.
Furthermore, the survey explores outlooks for three top producers of active pharmaceutical ingredients:
· Teva API
· Esteve Química
The investigation also assesses six Indian and Chinese companies:
· Dr. Reddy’s Laboratories
· Aurobindo Pharma
· Divis Laboratories
· Shandong Xinhua Pharmaceutical
· Zhejiang Hisun Pharmaceutical
· Zhejiang Huahai Pharmaceuticals.
That updated study profiles 30 top drug production contractors and analyses their industry. It shows historical data, market and sales shares, growth rates and revenue forecasts. The work also explores qualitative analyses, business outlooks and developments, giving 185 tables, 111 charts and three interviews with companies.
Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) – Market, Industry, Trends, Technologies and Prospects 2015-2025 adds to visiongain’s analytical reports on industries and markets in healthcare. Together those studies cover pharmaceuticals, medical devices, diagnostics, national markets, biotechnologies and outsourced services.